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GuidelinesWe read with interest the paper by Pant et al. (1) in a
recent issue of the Journal about the 2000 to 2011
trends of infective endocarditis (IE) in the United
States. A main conclusion is that the incidence of
streptococcal IE signiﬁcantly rose since 2007,
following the restriction of antibiotic prophylaxis of
IE in the American Heart Association (AHA) guidelines.
Streptococcal IE increased from 24.8% in 2000 to 27%
in 2011,with higher incidence in the 2007 to 2011 period
(2.22 cases per million population [1.64 to 2.80] vs.
0.85 cases per million population [0.50 to 1.20] in the
2000 to 2007 period) (1). The authors stated that their
results contrast with data from Duval et al. (2), who did
not report such an increase of streptococcal IE since the
guidelines were modiﬁed, because short follow-up
may preclude detection of this switch in the pattern
of streptococcal IE. They also claim that a steadyincrease in streptococcal IE has also been reported in
the United Kingdom since the National Institute for
Health and Care Excellence guidelines were changed
(3). However, U.K. guidelines not only limited indi-
cations for IE prophylaxis, but also completely stopped
them in 2008. Hence, comparisons between AHA and
National Institute for Health and Care Excellence
guidelines should be carefully made.
The major caveat of the contribution by Pant et al.
(1), however, is their neglect of enterococci. The
authors did not differentiate between enterococcal
and other streptococcal IE, pooling all together.
Enterococcal IE is a growing entity worldwide, espe-
cially in the United States, due to an aging population
with numerous comorbidities acquiring the infection
in the health care setting (4). Consequently,we suspect
that the increase of overall streptococcal IE is not
related to rising viridans group IE cases due to failing
AHA guidelines, but rather to an increase of entero-
coccal IE hidden in the work of Pant et al. (1). All
physicians must be aware of the “enterococcal
menace” and not get distracted with crying wolves.Juan M. Pericas, MD
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